

# Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia



Merel L. Hartgers, MD, Joep C. Defesche, PhD, Gisle Langslet, MD, Paul N. Hopkins, MD, MSPH, John J. P. Kastelein, MD, PhD, FESC, Marie T. Baccara-Dinet, MD, MSc, Werner Seiz, MD, Sara Hamon, MA, PhD, Poulabi Banerjee, PhD, Claudia Stefanutti, MD, PhD\*

*Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (Drs Hartgers and Kastelein); Department of Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands (Dr Defesche); Lipid Clinic, Oslo University Hospital, Oslo, Norway (Dr Langslet); School of Medicine, University of Utah, Salt Lake City, UT, USA (Dr Hopkins); Cardiovascular R&D, Sanofi, Montpellier, France (Dr Baccara-Dinet); Translational Medicine and Early Development, Sanofi, Frankfurt, Germany (Dr Seiz); Translational Medicine, Regeneron Pharmaceuticals, Inc., New York, NY, USA (Drs Hamon and Banerjee); and Department of Molecular Medicine, 'Sapienza' University of Rome, Umberto I Hospital, Rome, Italy (Dr Stefanutti)*

## KEYWORDS:

Alirocumab;  
Hypercholesterolemia;  
*LDLR*;  
*APOB*;  
*LDLRAP1*

**BACKGROUND:** Mutations in the genes for the low-density lipoprotein receptor (*LDLR*), apolipoprotein B, and proprotein convertase subtilisin/kexin type 9 have been reported to cause heterozygous and homozygous familial hypercholesterolemia (FH).

**OBJECTIVE:** The objective is to examine the influence of double heterozygous, compound heterozygous, or homozygous mutations underlying FH on the efficacy of alirocumab.

**METHODS:** Patients from 6 alirocumab trials with elevated low-density lipoprotein cholesterol (LDL-C) and FH diagnosis were sequenced for mutations in the *LDLR*, apolipoprotein B, proprotein convertase subtilisin/kexin type 9, *LDLR* adaptor protein 1 (*LDLRAP1*), and signal-transducing adaptor protein 1 genes. The efficacy of alirocumab was examined in patients who had double heterozygous, compound heterozygous, or homozygous mutations.

**RESULTS:** Of 1191 patients sequenced, 20 patients were double heterozygotes (n = 7), compound heterozygotes (n = 10), or homozygotes (n = 3). Mean baseline LDL-C levels were similar between patients treated with alirocumab (n = 11; 198 mg/dL) vs placebo (n = 9; 189 mg/dL). All patients treated with alirocumab 75/150 or 150 mg every 2 weeks had an LDL-C reduction of  $\geq 15\%$  at either week 12 or 24. At week 12, 1 patient had an increase of 7.1% in LDL-C, whereas in others, LDL-C was reduced by 21.7% to 63.9% (corresponding to 39–114 mg/dL absolute reduction from baseline). At week 24, LDL-C was reduced in all patients by 8.8% to 65.1% (10–165 mg/dL absolute reduction from baseline). Alirocumab was generally well tolerated in the 6 trials.

\* Corresponding author. Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, 'Sapienza' University of Rome, Umberto I Hospital, Rome, Italy.

E-mail address: [claudia.stefanutti@uniroma1.it](mailto:claudia.stefanutti@uniroma1.it)

Submitted November 17, 2017. Accepted for publication December 15, 2017.

**CONCLUSION:** Clinically meaningful LDL-C-lowering activity was observed in patients receiving alirocumab who were double heterozygous, compound heterozygous, or homozygous for genes that are causative for FH.

© 2018 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Mutations in the genes for the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), and proprotein convertase subtilisin/kexin type 9 (*PCSK9*) have been reported to cause heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), conditions which are characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of coronary heart disease.<sup>1–3</sup> Mutations in *LDLR* adaptor protein 1 (*LDLRAP1*) gene are recessive and cause HoFH.<sup>1</sup> LDL-C levels can vary markedly due to the phenotypic variability of mutations in the LDL-C pathway. Residual *LDLR* pathway activity correlates with disease severity and response to some lipid-lowering agents.<sup>4,5</sup> For example, the majority of patients who are *LDLR* negative have higher LDL-C levels and poorer clinical prognosis compared with patients who are *LDLR* defective.<sup>6,7</sup>

In general, patients with homozygous (identical mutations in both alleles) *LDLR* negative mutations or with compound heterozygous (different mutations in both alleles of the same gene) *LDLR* negative mutations have the highest mean LDL-C levels overall.<sup>5</sup> This is followed by those with compound heterozygous *LDLR* defective plus *LDLR* negative mutations, those with homozygous *LDLRAP1* or *LDLR* defective mutations, those with homozygous *APOB* or *PCSK9* gain-of-function (GOF) mutations, those with double heterozygous (mutations in 2 different genes) mutations, and then those with HeFH.<sup>5,8</sup> However, LDL-C level is the main determinant of cardiovascular disease risk and not the genetic defect *per se*.<sup>7,9</sup>

We have previously reported the effect of single mutations in genes causative for familial hypercholesterolemia (FH) in 1191 patients enrolled in 1 phase 2 and 5 phase 3 studies of the *PCSK9* antibody alirocumab.<sup>10</sup> Here, we focus on the treatment effect of alirocumab in patients with FH who were double heterozygotes, compound heterozygotes, or homozygotes.

## Methods

DNA samples from patients with a diagnosis of FH who were enrolled and provided written consent for participation in 6 clinical trials, and also provided written consent for the present genotyping analysis, were sequenced for mutations in genes causative for FH (*LDLR*, *APOB*, *PCSK9*, *LDLRAP1*, and signal-transducing adaptor protein 1). The trials included 1 phase 2 trial (NCT01375764)<sup>11</sup> and 5 phase 3 clinical trials from the ODYSSEY program (LONG TERM

[NCT01507831],<sup>12</sup> HIGH FH [NCT01617655],<sup>13</sup> FH I [NCT01623115], FH II [NCT01709500],<sup>14</sup> and ALTERNATIVE [NCT01709513]<sup>15</sup>). The original diagnosis of FH was performed either by previous genotyping or on clinical presentation. Clinical diagnosis was based on the Simon Broome criteria for definite FH or the World Health Organization/Dutch Lipid Network criteria (score >8 points).<sup>16–18</sup> The original genotyping results were not recorded in the trials; hence, patients were sequenced regardless of how they were originally diagnosed. Full details of the genotyping analysis for the present study have been described previously.<sup>10</sup>

The present analysis focuses on those patients who had more than 1 mutation in 1 or more of the sequenced genes. No patients from the ALTERNATIVE trial were found to have more than 1 mutation. Study designs of the other trials were as follows. In the 12-week phase 2 study, patients received 1 of 4 alirocumab doses (150 mg every 2 weeks [Q2W], 150 mg every 4 weeks [Q4W], 200 mg Q4W, 300 mg Q4W) or placebo.<sup>11</sup> In the 78-week phase 3 trials, patients received either alirocumab 150 mg Q2W (LONG TERM and HIGH FH) or an initial alirocumab dose of 75 mg Q2W, which was increased to 150 mg Q2W at week 12 if LDL-C was  $\geq 70$  mg/dL at week 8 (FH I and FH II); control was placebo in each trial.<sup>12–14</sup> The primary efficacy endpoint in the phase 3 trials was the percentage reduction in LDL-C from baseline to week 24. Safety assessments included treatment-emergent adverse events, which were events occurring from first to last dose and up to 70 days after the last dose (follow-up).

LDL-C levels were calculated using the Friedewald equation<sup>19</sup> except when triglyceride levels exceeded 400 mg/dL, in which case LDL-C was determined by direct measurement using beta quantification.<sup>20</sup> In this post hoc analysis, a clinically meaningful response to alirocumab was defined as a reduction in LDL-C of  $\geq 15\%$  at week 12 or 24 (the available timepoints), as described previously.<sup>10</sup> Analysis of lipid and lipoprotein parameters was performed at a central laboratory. Lipoprotein (a) [Lp(a)] levels were analyzed using a validated immunoturbidimetric assay as previously described.<sup>21</sup>

## Results

### Patients

Of 1191 patients sequenced, 20 patients were double heterozygous (n = 7), compound heterozygous (n = 10), or

homozygous (n = 3) for genes causative of FH and included in the present analysis (Table 1). Six patients were double heterozygotes with mutations in both *APOB* and *LDLR*, of whom 3 patients were *APOB* defective/*LDLR* negative and the remaining 3 *APOB* defective/*LDLR* defective. One patient was double heterozygote with *LDLR* negative and *PCSK9* GOF mutations. Of those who were compound heterozygotes, 3 were *LDLR* defective/*LDLR* negative, and 7 were *LDLR* defective/*LDLR* defective. Of the 3 patients who were homozygotes, 1 had *LDLR* defective mutations (further details on this patient are presented in the Supplementary Material) and 2 were homozygous for mutations in *LDLRAP1*.

In this analysis, 11 of 20 patients received alirocumab, and the remaining 9 received placebo (Table 1). The mean age at baseline was 49.2 years, and 50% were males. Baseline characteristics of individual patients are presented in Supplementary Table 1. The mean baseline LDL-C level was 198 mg/dL for those treated with alirocumab and 189 mg/dL for those treated with placebo. All patients were receiving concomitant statin, and the majority were receiving additional lipid-lowering therapies at baseline (Supplementary Table 1). Most patients were at very-high cardiovascular risk at baseline. The cardiovascular history of individual

patients at baseline is presented in Supplementary Table 2.

### Influence of double heterozygous, compound heterozygous, or homozygous mutations on the efficacy of alirocumab

Percentage changes from baseline in LDL-C at weeks 12 and 24 for individual patients with available data are shown in Figure 1; absolute changes are shown in Supplementary Table 3. In this analysis, an LDL-C reduction of  $\geq 15\%$  at week 12 or 24 was observed in patients who had received alirocumab 75/150 or 150 mg Q2W (Fig. 1). At week 12, an LDL-C reduction of 21.7% to 63.9% (corresponding to 39–114 mg/dL absolute reduction) with alirocumab treatment was observed in all but 1 patient (patient 10, *LDLRAP1* negative, baseline LDL-C 140 mg/dL, from the FH I study) who had an LDL-C increase of 7.1%; however, this patient had an LDL-C reduction of 34.3% (absolute reduction of 48 mg/dL) from baseline to week 24. LDL-C reduction from baseline to week 24 in other patients was 8.8% to 65.1% (absolute reduction of 10–165 mg/dL).

Furthermore, patient 5 (*LDLR* defective/*LDLR* negative from the FH II study) had an LDL-C reduction of 52.6% (absolute reduction of 60 mg/dL from baseline value of 114 mg/dL) at week 12, compared with a reduction of


**Table 1** Distribution of mutations and treatment received by each patient (sequenced cohort)

Patient number	Study	Mutation category	Genotype	Treatment
1	FH I	<i>APOB</i> defective/ <i>LDLR</i> negative	p.Arg3527Gln.c.1846-?_2140+?del	Alirocumab 75/150 mg Q2W <sup>†</sup>
2 <sup>‡</sup>	HIGH FH	<i>APOB</i> defective/ <i>LDLR</i> negative	p.Arg3527Gln.2390-?_2583+?del	Alirocumab 150 mg Q2W
3	FH I	<i>APOB</i> defective/ <i>LDLR</i> defective	p.Arg3527Gln.p.Asp227Glu	Alirocumab 75/150 mg Q2W <sup>†</sup>
4	FH II	<i>APOB</i> defective/ <i>LDLR</i> defective	p.Arg3527Gln.p.Cys209Tyr	Alirocumab 75/150 mg Q2W <sup>†</sup>
5	FH II	<i>LDLR</i> defective/ <i>LDLR</i> negative	c.(-16)G>C.p.Trp562*	Alirocumab 75/150 mg Q2W <sup>†</sup>
6	FH II	<i>LDLR</i> defective/ <i>LDLR</i> negative	c.313+1G>A.p.Val462Ile	Alirocumab 75/150 mg Q2W <sup>†</sup>
7	R727-CL-1003 phase 2	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Arg81Cys.c.(-268)G>T	Alirocumab 150 mg Q2W
8	HIGH FH	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Asp266Asn.p.Gly592Glu	Alirocumab 150 mg Q2W
9	HIGH FH	<i>LDLR</i> defective homozygous	p.Asp227Glu.p.Asp227Glu	Alirocumab 150 mg Q2W
10	FH I	<i>LDLRAP1</i> negative	c.344+1G>A.c.344+1G>A	Alirocumab 75/150 mg Q2W <sup>†</sup>
11	R727-CL-1003 Phase 2	<i>LDLR</i> negative/ <i>PCSK9</i> GOF	p.Cys143.p.Leu22_Leu23dup	Alirocumab 150 mg Q4W
12	FH I	<i>APOB</i> defective/ <i>LDLR</i> negative	p.Arg3527Gln.p.Tyr375Trpfs*7	Placebo
13	FH I	<i>APOB</i> defective/ <i>LDLR</i> defective	p.Arg3527Gln.p.Gly478Arg	Placebo
14	FH I	<i>LDLR</i> defective/ <i>LDLR</i> negative	p.Glu600Asp.c.191-?_1060+?del	Placebo
15	FH I	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Glu408Lys.p.Gln770Arg	Placebo
16	FH I	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Glu337Lys.p.Asp482Asn	Placebo
17	LONG TERM	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Asp651Asn.p.Asp221Gly	Placebo
18	LONG TERM	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Asp700Glu.p.Asp227Glu	Placebo
19	LONG TERM	<i>LDLR</i> defective/ <i>LDLR</i> defective	p.Leu432Val.p.Tyr465Asn.p.Pro685Leu	Placebo
20	LONG TERM	<i>LDLRAP1</i> negative	p.Gly24Alafs*32.p.Gly24Alafs*32	Placebo

*APOB*, apolipoprotein B; GOF, gain-of-function; LDL-C, low-density lipoprotein cholesterol; *LDLR*, low-density lipoprotein receptor; *LDLRAP1*, LDL receptor adaptor protein 1; *PCSK9*, proprotein convertase subtilisin/kexin type 9; Q2W, every 2 weeks; Q4W, every 4 weeks.

<sup>†</sup>Alirocumab 75 mg Q2W was increased to 150 mg Q2W at week 12 depending on LDL-C at week 8.

<sup>‡</sup>Data for all lipid endpoints were not available for patient 2.



**Figure 1** Percentage change from baseline in LDL-C at (A) week 12 and (B) week 24 for individual patients. Data were not available for patient 2 (*APOB* defective/*LDLR* negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (*PCSK9* GOF and *LDLR* negative) received a different alirocumab administration regimen and is not included in this figure. *APOB*, apolipoprotein B; LDL-C, low-density lipoprotein cholesterol; *LDLR*, low-density lipoprotein receptor; *LDLRAP1*, LDLR adaptor protein 1; N/A, not available.

8.8% (absolute reduction of 10 mg/dL) at week 24. Patient 9 (*LDLR*-defective homozygous from the HIGH FH study) had an LDL-C reduction of 22.9% (absolute reduction of 92 mg/dL from baseline value of 402 mg/dL) at week 12 compared with a reduction of 11.9% (absolute reduction of 48 mg/dL) at week 24.

Overall, alirocumab treatment provided LDL-C reductions of 39.3% to 55.7% and 55.1% to 62.0% in patients with double heterozygous mutations (*APOB* defective/*LDLR* negative and *APOB* defective/*LDLR* defective) at weeks 12 and 24, respectively. The corresponding reductions in patients with compound heterozygous mutations (*LDLR* defective/*LDLR* negative and *LDLR* defective/*LDLR* defective) were 21.7% to 63.9% and 8.8% to 65.1% at weeks 12 and 24, respectively.

At week 12, 2 patients (patients 5 and 6, both *LDLR* defective/*LDLR* negative) achieved an LDL-C level of <70 mg/dL with alirocumab treatment. In addition, 2 patients (patient 1 [*APOB* defective/*LDLR* negative] and patient 4 [*APOB* defective/*LDLR* defective]) achieved LDL-C <100 mg/dL.

Overall, the LDL-C levels were maintained in these patients at week 24 except in patient 5 who had an LDL-C level of 104 mg/dL, compared with 54 mg/dL at week 12.

Reductions with alirocumab treatment at weeks 12 and 24 were also observed across the mutation backgrounds in ApoB, Lp(a), non-high-density lipoprotein cholesterol, and triglycerides (Supplementary Figs. 1–4). The patient with the *PCSK9* GOF and *LDLR* negative mutations (patient 11) received a different administration regimen of alirocumab (150 mg Q4W) in the phase 2 study and is not included in Figure 1 or Supplementary Figures 1–4; an LDL-C reduction of 44.1% (corresponding to 60 mg/dL absolute reduction in LDL-C from baseline value of 136 mg/dL) was observed at week 10, 2 weeks after the last alirocumab dose was administered.

## Safety

Safety data for all patients sequenced for mutations in genes causative for FH (n = 1191) have been reported

previously.<sup>10</sup> The rates of treatment-emergent adverse events in the overall sequenced cohort were comparable for alirocumab (82.9%) vs comparator (83.3%; comparator included placebo as well as ezetimibe).<sup>10</sup> The incidence of injection-site reactions (mostly mild and transient) was higher for alirocumab (11.4%) vs comparator (8.8%).<sup>10</sup> Given the small population (n = 20) for the present analysis, no further safety analysis was performed for this specific cohort.

## Discussion

In the present analysis, we identified 20 patients with double heterozygous, compound heterozygous, and homozygous FH mutations, from 6 of the alirocumab clinical trials. All patients who received alirocumab 75/150 or 150 mg Q2W (the majority of whom were receiving background statins) in the trials responded to treatment (defined by LDL-C reduction  $\geq 15\%$  on at least week 12 or 24). At week 12, alirocumab treatment resulted in LDL-C reductions of 21.7% to 63.9% (absolute reductions of 39–114 mg/dL) in all but 1 patient (patient 10; a 39-year-old female with *LDLRAP1*-negative mutations) who had an increase of 7.1% in LDL-C (baseline LDL-C was 140 mg/dL); however, a reduction of 34.3% (absolute reduction of 48 mg/dL) from baseline to week 24 was observed in this patient, following alirocumab dose increase from 75 mg Q2W to 150 mg Q2W at week 12.

Furthermore, 2 alirocumab-treated patients showed inconsistent LDL-C reductions at week 12 vs week 24. Patient 5 had an LDL-C reduction of 52.6% and 8.8% at weeks 12 and 24, respectively. The corresponding values for patient 9 were 22.9% and 11.9%, respectively. Although there is no firm explanation for the differences in response between week 12 and week 24 LDL-C reductions in these patients, nonadherence to therapy cannot be excluded.

Reductions of 24% to 30% in LDL-C, regardless of baseline levels, have been reported to provide clinical benefits, including reduced risks of cardiovascular events and deaths.<sup>22–24</sup> With the range of LDL-C reductions observed in this analysis, patients with more than 1 FH mutation will be expected to have reduced cardiovascular risks with alirocumab treatment. At week 12, although only 2 and 4 alirocumab-treated patients achieved risk-specific LDL-C goals of  $<70$  mg/dL or  $<100$  mg/dL, respectively, those who did not achieve the LDL-C goals had reductions of 21.7% to 39.3%, equivalent to 39 to 114 mg/dL absolute reductions in LDL-C (despite high baseline LDL-C level of  $\geq 180$  mg/dL). With these high baseline LDL-C levels, achievement of LDL-C  $<70$  mg/dL is unlikely, but these patients will be expected to have reduced risk of cardiovascular events and improved survival with the observed reductions in their LDL-C.

The LDLR mediates uptake of low-density lipoprotein (LDL) particles into the liver cell, via interaction with the ApoB component of LDL. PCSK9 binds to the LDLR and

prevents the receptor recycling to the cell surface, targeting the LDLR for degradation by endocytosis. Inhibition of PCSK9 with the monoclonal antibody alirocumab reduces LDL-C levels by increasing the level of LDLRs on the liver cell surface, resulting in an increased uptake of LDL particles.<sup>25</sup> Therefore alirocumab's mode of action involves the LDLR, ApoB, and PCSK9 (and likely other proteins such as *LDLRAP1*, which interacts with the LDLR), and mutations in genes encoding these proteins could conceivably impact the treatment effect of alirocumab. For example, complete loss of both copies of *LDLR* may be expected to nullify the effect of a PCSK9 inhibitor. Indeed, another PCSK9 inhibitor showed no effect on LDL-C levels when examined in 3 patients with *LDLR* negative/negative mutations,<sup>26,27</sup> with similar results seen in a large open-label study.<sup>28</sup> None of the patients examined in our analysis was *LDLR* negative/negative.

In this analysis, alirocumab treatment provided substantial reductions in LDL-C in patients with FH and residual *LDLR* function (including patients with mutations in both copies of the gene). Double heterozygous mutations in *APOB* and *LDLR* appeared not to influence the efficacy of alirocumab, with reductions in the same range as reported for the overall pooled analysis of FH patients from alirocumab phase 3 trials (mean reductions from baseline to week 24 of 48.8% and 55.0% with alirocumab doses of 75 mg Q2W [with possible dose increase to 150 mg Q2W at week 12] and 150 mg Q2W, respectively).<sup>29</sup>

Published data have shown a mean reduction in LDL-C of 29.6% at week 12 in 20 HoFH patients with *LDLR* defective mutations in one or both alleles, following biweekly treatment with another PCSK9 inhibitor, supporting the efficacy of PCSK9 inhibitors in patients with defective *LDLR* function.<sup>27</sup> In our study, alirocumab 75/150 or 150 mg Q2W treatment in 7 patients with defective *LDLR* function (patients 3–9) provided LDL-C reductions of 21.7% to 63.9% at week 12, a mean reduction of 41.2%. Of note, this includes patients who also have other mutations including defective *APOB* function (patients 3 and 4) and negative *LDLR* function (patients 5 and 6).

Alirocumab treatment resulted in LDL-C reduction in the patient with *LDLR* negative and *PCSK9* GOF mutations, lending further support to previously published results suggesting that *PCSK9* GOF mutations in general do not impair the efficacy of alirocumab<sup>30</sup>; similar findings were observed with another PCSK9 inhibitor.<sup>28</sup>

Previous reports have indicated mean reductions in Lp(a) of approximately 20% with alirocumab treatment.<sup>21</sup> Lp(a) is known to be an independent risk factor for cardiovascular disease.<sup>31</sup> In the present analysis, Lp(a) reductions with alirocumab varied between week 12 and week 24. At week 24, reductions in the range 19.8% to 49.5% were observed across the patients treated with alirocumab, although (for reasons that are unclear) 2 patients (with *LDLRAP1* and *LDLR* defective homozygous mutations, respectively) did not have an Lp(a) reduction at week 24.

Baseline Lp(a) levels also varied considerably between patients (25–99 mg/dL).

The alirocumab safety profile in the cohort of sequenced patients was comparable between those who received alirocumab or placebo,<sup>10</sup> consistent with pooled safety data from the overall FH populations of alirocumab phase 3 trials.<sup>29</sup>

## Limitations

Limitations of this post hoc analysis include the small number of patients with each mutation type; however, this is inevitable given the rarity of these mutations. Furthermore, patients with a known history of HoFH were excluded in the individual clinical trials, and so very few patients with HoFH were included in the present analysis. However, in general, the data are robust, with low heterogeneity. The analysis was well controlled with a similar group of patients who received placebo during the study. The impact of rare mutation types may be better assessed in specifically designed trials using a placebo-phase approach, whereby each patient acts as their own control, as previously described.<sup>30</sup>

## Conclusion

A clinically meaningful LDL-C-lowering activity was observed in patients receiving alirocumab who are double or compound heterozygous, or homozygous for genes that are causative for FH, such as *LDLR*, *APOB*, *PCSK9*, and *LDLRAP1*. LDL-C-lowering activity of alirocumab in these mutations is likely to be attributable to the presence of at least 1 partially functional allele.

## Acknowledgments

The authors would like to thank the patients, their families, and all investigators involved in this study. Medical writing assistance and editorial support, under the direction of the authors, was provided by Emmanuel Ogunnowo, PhD, and Rob Campbell, PhD, both of Prime (Knutsford, UK), funded by Sanofi and Regeneron Pharmaceuticals, Inc. according to Good Publication Practice guidelines. Responsibility for all opinions, conclusions, and data interpretation lies with the authors.

Author contributions: Merel L. Hartgers contributed in interpretation of data; Joep C. Defesche in interpretation of data; Gisle Langslet in acquisition of data (trial investigator) and interpretation of data; Paul N. Hopkins in interpretation of data; John J. P. Kastelein in concept/design, acquisition of data (trial investigator), and interpretation of data; Marie T. Baccara-Dinet in interpretation of data; Werner Seiz in concept/design and interpretation of data; Sara Hamon in concept/design and interpretation of data. Poulabi Banerjee in concept/design and interpretation of data; Claudia Stefanutti in interpretation of data. All authors were involved in critical review of manuscript drafts and approved the final article for submission.

Role of the funding source: This analysis was funded by Sanofi and Regeneron Pharmaceuticals, Inc., who were involved in the study design, collection, analysis, and interpretation of data. The authors had unrestricted access to study data, were responsible for all content and editorial decisions, and made the final decision to submit the manuscript for publication.

## Financial disclosures

Merel Hartgers and Joep Defesche have nothing to disclose. Gisle Langslet received honoraria for consultancy and is a member of advisory boards in Amgen, Sanofi-Aventis, Boehringer Ingelheim, and Janssen Pharmaceuticals; Paul N. Hopkins received research support from Sanofi/Regeneron Pharmaceuticals, Inc., Merck, and Takeda; John J. P. Kastelein received honoraria from Dezima Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi, Eli Lilly, Pfizer, Amgen, Genzyme, Aegerion, Esperion, and Ionis Pharmaceuticals and honoraria for consultancy/advisory boards from Dezima Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Sanofi, Eli Lilly, Pfizer, Amgen, Genzyme, Aegerion, Esperion, and Ionis Pharmaceuticals; Marie T. Baccara-Dinet and Werner Seiz are employees of and stockholders in Sanofi. Sara Hamon and Poulabi Banerjee are employees of and stockholders in Regeneron Pharmaceuticals, Inc; Claudia Stefanutti received honoraria from Kaneka Pharma NV Europe, Fresenius Medical Care, Merck Sharp and Dohme, B. Braun, Amryt, and Aegerion and received research support from Regeneron Pharmaceuticals, Inc., Ionis Pharmaceuticals, Amgen, and Kowa.

## References

1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J*. 2013;34:3478–3490a.
2. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. *Nat Clin Pract Cardiovasc Med*. 2007;4:214–225.
3. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. *Atherosclerosis*. 2012;223:262–268.
4. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *J Clin Invest*. 2003;111:1795–1803.
5. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J*. 2014;35:2146–2157.
6. Moorjani S, Roy M, Torres A, et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. *Lancet*. 1993;341:1303–1306.

7. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38:2459–2472.
8. Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes Endocrinol*. 2016;4:850–861.
9. Hartgers ML, Hovingh GK, Kastelein JJ, Huijgen R. Familial hypercholesterolemia: classification of mutation severity according to percentile low-density lipoprotein cholesterol useful for predicting coronary artery disease risk. *Circulation*. 2016;134:A19939.
10. Defesche JC, Stefanutti C, Langslet G, et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. *J Clin Lipidol*. 2017;11:1338–1346.e7.
11. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. *Lancet*. 2012;380:29–36.
12. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med*. 2015;372:1489–1499.
13. Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. *Cardiovasc Drugs Ther*. 2016;30:473–483.
14. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *Eur Heart J*. 2015;36:2996–3003.
15. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol*. 2015;9:758–769.
16. Defesche JC. Familial hypercholesterolaemia. In: Betteridge DJ, editor. *Lipids and Vascular Disease*. London: Martin Dunitz Ltd., 2000. p. 65–76.
17. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. *BMJ*. 1991;303:893–896.
18. World Health Organization. Familial Hypercholesterolaemia (FH): Report of a second WHO consultation. Available at: [whqlibdoc.who.int/hq/1999/WHO\\_HGN\\_FH\\_CONS\\_99.2.pdf](http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdf). Accessed January 15, 2018.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499–502.
20. Belcher J, McNamara J, Gregory F. Measurement of low density lipoprotein cholesterol concentration. In: Rifai N, Warnick G, editors. *Methods for Clinical Laboratory Measurement of Lipid and Lipoprotein Risk Factors*. Washington, DC: AACC Press, 1991. p. 80–81.
21. Gaudet D, Watts GF, Robinson JG, et al. Effect of Alirocumab on Lipoprotein(a) Over  $\geq 1.5$  Years (from the Phase 3 ODYSSEY Program). *Am J Cardiol*. 2017;119:40–46.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383–1389.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7–22.
24. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267–1278.
25. Seidah NG. New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications. *Curr Opin Lipidol*. 2016;27:274–281.
26. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. *Circulation*. 2013;128:2113–2120.
27. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385:341–350.
28. Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. *Lancet Diabetes Endocrinol*. 2017;5:280–290.
29. Kastelein JJ, Hovingh GK, Langslet G, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. *J Clin Lipidol*. 2017;11:195–203.e194.
30. Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. *Circ Cardiovasc Genet*. 2015;8:823–831.
31. Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. *J Am Coll Cardiol*. 2014;63:1982–1989.

### **Further details for patient with homozygous familial hypercholesterolemia**

In this analysis, 1 patient (patient 9) was genotyped as having homozygous low-density lipoprotein receptor (*LDLR*)-defective mutations. This patient was a 28-year-old male with homozygous familial hypercholesterolemia diagnosed at the age of 5 years. The patient was treated with simvastatin 80 mg and nicotinic acid 1500 mg daily; he had a body mass index of 23 kg/m<sup>2</sup>. Xanthomas were present on both knees. Medical history was hypertension, aortic stenosis, and stable angina. The patient had baseline LDL-C 402 mg/dL and was treated with alirocumab 150 mg every 2 weeks, achieving an LDL-C reduction of 22.9% at week 12.



**Supplementary Table 1** Patient characteristics at baseline

Patient number	Age (y)	Gender	Mutation category	LDL-C (mg/dL)	ApoB (mg/dL)	Lp(a) (mg/dL)	Non-HDL-C (mg/dL)	Triglycerides (mg/dL)	Statin	Other LLTs
1	59	F	<i>APOB</i> defective/ <i>LDLR</i> negative	167	137	99	191	120	Rosuvastatin 20 mg	Ezetimibe
2	50	F	<i>APOB</i> defective/ <i>LDLR</i> negative	155	113	2	183	138	Rosuvastatin 40 mg	NA
3	69	F	<i>APOB</i> defective/ <i>LDLR</i> defective	290	168	25	317	137	Atorvastatin 80 mg	Ezetimibe
4	47	F	<i>APOB</i> defective/ <i>LDLR</i> defective	150	109	38	165	73	Rosuvastatin 40 mg	Ezetimibe
5	61	F	<i>LDLR</i> defective/ <i>LDLR</i> negative	114	87	86	126	61	Atorvastatin 80 mg	Ezetimibe
6	58	F	<i>LDLR</i> defective/ <i>LDLR</i> negative	166	124	54	187	104	Atorvastatin 80 mg	Ezetimibe, bile acid sequestrants
7	36	M	<i>LDLR</i> defective/ <i>LDLR</i> defective	205	162	38	233	139	Simvastatin 40 mg, rosuvastatin 10 mg	Fish oil, nicotinic acid
8	31	M	<i>LDLR</i> defective/ <i>LDLR</i> defective	180	124	80	194	68	Rosuvastatin 40 mg	NA
9	28	M	<i>LDLR</i> defective homozygous	402	202	69	419	83	Simvastatin 80 mg	Nicotinic acid
10	39	F	<i>LDLRAP1</i> negative	140	100	71	149	43	Atorvastatin 80 mg	Ezetimibe, fenofibrate
11	54	M	<i>LDLR</i> negative/ <i>PCSK9</i> GOF	136	NA	NA	NA	NA	Rosuvastatin 40 mg	Ezetimibe
12	58	F	<i>APOB</i> defective/ <i>LDLR</i> negative	296	203	50	336	198	Atorvastatin 80 mg	Ezetimibe, fish oil
13	54	M	<i>APOB</i> defective/ <i>LDLR</i> defective	163	120	91	175	61	Atorvastatin 80 mg	Ezetimibe, nicotinic acid
14	35	M	<i>LDLR</i> defective/ <i>LDLR</i> negative	167	138	2	201	169	Rosuvastatin 20 mg	Ezetimibe
15	60	M	<i>LDLR</i> defective/ <i>LDLR</i> defective	142	132	185	170	142	Rosuvastatin 40 mg	Ezetimibe, fish oil, bile acid sequestrants
16	59	M	<i>LDLR</i> defective/ <i>LDLR</i> defective	164	128	178	185	103	Rosuvastatin 40 mg	Ezetimibe, nicotinic acid, bile acid sequestrants
17	51	M	<i>LDLR</i> defective/ <i>LDLR</i> defective	232	164	115	252	102	Rosuvastatin 40 mg	Ezetimibe
18	49	F	<i>LDLR</i> defective/ <i>LDLR</i> defective	192	119	2	207	73	Simvastatin 40 mg	N/A
19	41	F	<i>LDLR</i> defective/ <i>LDLR</i> defective	208	143	4	227	93	Rosuvastatin 40 mg	Ezetimibe, bile acid sequestrants
20	45	M	<i>LDLRAP1</i> negative	141	110	2	156	74	Rosuvastatin 40 mg	Ezetimibe, nicotinic acid

ApoB, apolipoprotein B; F, female; GOF, gain-of-function; LDL-C, low-density lipoprotein cholesterol; *LDLR*, low-density lipoprotein receptor; *LDLRAP1*, LDLR adaptor protein 1; Lp(a), lipoprotein(a); M, male; NA, not available; non-HDL-C, non-high-density lipoprotein cholesterol; *PCSK9*, proprotein convertase subtilisin/kexin type 9.

**Supplementary Table 2** Cardiovascular history at baseline

Patient number	Dictionary-derived term for reported cardiovascular history	Categorization of cardiovascular risk per protocol
1	Coronary revascularization, coronary artery disease, cardiac catheterization, angina pectoris, familial risk factor, mitral valve prolapse, unstable angina, coronary artery bypass, cardiac stress test	Very-high cardiovascular risk
2	Hypertension	High cardiovascular risk
3	Hypertension, familial risk factor, type 2 diabetes mellitus	Very-high cardiovascular risk
4	Coronary artery disease, cardiac stress test, carotid arteriosclerosis	Very-high cardiovascular risk
5	Coronary revascularization, coronary artery disease, familial risk factor, angina pectoris, acute myocardial infarction, unstable angina, percutaneous coronary intervention	Very-high cardiovascular risk
6	Hypertension, intermittent claudication, ankle-brachial index, cardiac murmur, familial risk factor	Very-high cardiovascular risk
7	None reported	Not applicable
8	Coronary revascularization, coronary artery disease, arteriosclerosis, arteriosclerosis coronary artery, angina pectoris, coronary angioplasty, coronary arterial stent insertion	Very-high cardiovascular risk
9	Coronary artery disease, familial risk factor, hypertension, aortic stenosis, angina pectoris	Very-high cardiovascular risk
10	Sinus bradycardia, abdominal bruit, carotid bruit, cardiac murmur, familial risk factor	High cardiovascular risk
11	None reported	Not applicable
12	None reported	Not applicable
13	Coronary revascularization, coronary artery disease, acute myocardial infarction, percutaneous coronary intervention	Very-high cardiovascular risk
14	None reported	Not applicable
15	Coronary revascularization, familial risk factor, acute myocardial infarction, coronary artery disease, coronary artery bypass, coronary angioplasty, unstable angina, coronary arterial stent insertion, myocardial infarction, ventricular extrasystoles	Very-high cardiovascular risk
16	Coronary revascularization, familial risk factor, coronary artery disease, acute myocardial infarction, coronary artery bypass, hypertension, type 2 diabetes mellitus, coronary arterial stent insertion, percutaneous coronary intervention, dyslipidemia, abnormal lipoprotein	Very-high cardiovascular risk
17	Familial risk factor, coronary revascularization, coronary arterial stent insertion, hypertension, acute myocardial infarction, unstable angina, coronary artery disease	Very-high cardiovascular risk
18	None reported	Not applicable
19	Acute myocardial infarction, coronary revascularization, bradycardia	Very-high cardiovascular risk
20	Coronary revascularization, coronary artery disease, familial risk factor, acute myocardial infarction	Very-high cardiovascular risk


**Supplementary Table 3** Change in LDL-C from baseline to weeks 12 and 24

Patient number	Treatment <sup>†</sup>	Baseline LDL-C (mg/dL)	LDL-C at Wk 12 (mg/dL)	Change in LDL-C from baseline to Wk 12 (mg/dL)	LDL-C at Wk 24 (mg/dL)	Change in LDL-C from baseline to Wk 24 (mg/dL)
1	Alirocumab 75/150 mg Q2W	167	74	-93	75	-92
3	Alirocumab 75/150 mg Q2W	290	176	-114	125	-165
4	Alirocumab 75/150 mg Q2W	150	71	-79	57	-93
5	Alirocumab 75/150 mg Q2W	114	54	-60	104	-10
6	Alirocumab 75/150 mg Q2W	166	60	-106	58	-108
7	Alirocumab 150 mg Q2W	205	133	-72	NA	NA
8	Alirocumab 150 mg Q2W	180	141	-39	127	-53
9	Alirocumab 150 mg Q2W	402	310	-92	354	-48
10	Alirocumab 75/150 mg Q2W	140	150	+10	92	-48
12	Placebo	296	292	-4	358	+62
13	Placebo	163	155	-8	155	-8
14	Placebo	167	161	-6	152	-15
15	Placebo	142	147	+5	159	+17
16	Placebo	164	153	-11	201	+37
17	Placebo	232	237	+5	180	-52
18	Placebo	192	209	+17	223	+31
19	Placebo	208	174	-34	207	-1
20	Placebo	141	147	+5	149	+8


LDL-C, low-density lipoprotein cholesterol; NA, not available; Q2W, every 2 weeks.

Data were not available for patient 2 (*APOB* defective/*LDLR* negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (*PCSK9* GOF and *LDLR* negative) received a different alirocumab administration regimen and is not included in this table.

<sup>†</sup>Alirocumab 75 mg Q2W was increased to 150 mg Q2W at week 12 depending on LDL-C at week 8.




**Supplementary Figure 1** Percentage change from baseline in ApoB at weeks 12 and 24. Data were not available for patient 2 (*APOB* defective/*LDLR* negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (*PCSK9* GOF and *LDLR* negative) received a different alirocumab administration regimen and is not included in this figure. *APOB*, apolipoprotein B; *LDLR*, low-density lipoprotein receptor; *LDLRAP1*, LDLR adaptor protein 1; NA, not available.




- APOB defective/LDLR negative
- APOB defective/LDLR defective
- LDLR defective/LDLR negative
- LDLR defective/LDLR defective
- LDLR defective homozygous
- LDLRAP1 negative

**Supplementary Figure 2** Percentage change from baseline in Lp(a) at weeks 12 and 24. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different aliocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; Lp(a), lipoprotein (a); NA, not available.



- *APOB* defective/*LDLR* negative
- *APOB* defective/*LDLR* defective
- *LDLR* defective/*LDLR* negative
- *LDLR* defective/*LDLR* defective
- *LDLR* defective homozygous
- *LDLRAP1* negative

**Supplementary Figure 3** Percentage change from baseline in non-HDL-C at weeks 12 and 24. Data were not available for patient 2 (*APOB* defective/*LDLR* negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (*PCSK9* GOF and *LDLR* negative) received a different alirocumab administration regimen and is not included in this figure. *APOB*, apolipoprotein B; *LDLR*, low-density lipoprotein receptor; *LDLRAP1*, LDLR adaptor protein 1; non-HDL-C, non-high-density lipoprotein cholesterol.



- APOB defective/LDLR negative
- APOB defective/LDLR defective
- LDLR defective/LDLR negative
- LDLR defective/LDLR defective
- LDLR defective homozygous
- LDLRAP1 negative

**Supplementary Figure 4** Percentage change from baseline in triglycerides at weeks 12 and 24. Data were not available for patient 2 (APOB defective/LDLR negative). Patient 7 was from the 12-week phase 2 study therefore no data were available at week 24. Patient 11 (PCSK9 GOF and LDLR negative) received a different alirocumab administration regimen and is not included in this figure. APOB, apolipoprotein B; LDLR, low-density lipoprotein receptor; LDLRAP1, LDLR adaptor protein 1; NA, not available.